Compare PBYI & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBYI | NAKA |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 265.2M |
| IPO Year | N/A | 2024 |
| Metric | PBYI | NAKA |
|---|---|---|
| Price | $5.96 | $0.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $7.00 | $4.50 |
| AVG Volume (30 Days) | 372.8K | ★ 13.5M |
| Earning Date | 11-06-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $211,995,000.00 | $1,980,278.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,774.04 |
| P/E Ratio | $8.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.58 | $0.34 |
| 52 Week High | $6.12 | $34.77 |
| Indicator | PBYI | NAKA |
|---|---|---|
| Relative Strength Index (RSI) | 66.14 | 34.50 |
| Support Level | $5.51 | $0.34 |
| Resistance Level | $5.73 | $0.45 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 95.76 | 23.61 |
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.